Regulators of cytokine signalling in rheumatoid arthritis

Rheumatology

Volumn 46, Issue 12, 2007, Pages 1745-1746

  Rahman, Anisur ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CELL SURFACE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; RITUXIMAB; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYROSINE;

CARBOXY TERMINAL SEQUENCE; DISEASE ACTIVITY; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOLOGICAL TOLERANCE; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SYNOVIAL MEMBRANE;

EID: 36448939769     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem285     Document Type: Editorial

References (19)

1. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methatrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Weinblatt ME, Kromer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:FC fusion protein, in patients with rheumatoid arthritis receiving methatrexate. N Engi J Med 1999;340:253-9.
3. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
4. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-call-targeted therapy with dtuximab in patents with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
5. O'Shea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet? Immunity 1997;7:1-11.
6. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003;4:1169-76.
7. Starr R, Willson TA, Viney EM et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21.
8. Endo TA, Masuhara M, Yokouchi M et al. A new protein containing an SH2 domain that inhibits JAK Idnases. Nature 1997;387:921-4.
9. Naka T, Narazaki M, Hirata M et al. Structure and function of a now STAT-induced STAT inhibitor. Nature 1997;387:924-9.
10. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002;2:410-6.
11. Rottapel R. Putting the brakes on arthritis: Can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis? J Clin Invest 2001;108:1745-7.
12. Alexander WS, Starr R, Fenner JE et al. SOCSI is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
13. Ernst M, Inglese M, Waring P et al. Defective gp130-madiated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 2001;194:189-203.
14. Egan PJ, Lawlor KE, Alexander WS, Wicks IP. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T call activation. J Clin Invest 2003;111:915-24.
15. Wong PK, Egan PJ, Croker BA et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 2006;116:1571-81.
16. Atsumi T, Ishihara K, Kamimura D et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002;196:979-90.
17. Shouda T, Yoshida T, Hanada T et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001;108:1781-8.
18. Yamana J, Yamamura M, Okamoto A et al. Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2004;6:R567-77.
19. Isomaki P, Alanara T, Isohanni P et al. The expression of SOCS is altered in rheumatoid arthritis. Rheumatology 2007;46:1538-46.